A5064151962- Cancer Immunotherapy and Biomarkers
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- CAR-T cell therapy research
- Cancer, Stress, Anesthesia, and Immune Response
- Cancer Genomics and Diagnostics
- Global Cancer Incidence and Screening
- HER2/EGFR in Cancer Research
- Immunotherapy and Immune Responses
- Cancer Risks and Factors
- Cancer Treatment and Pharmacology
- Chemokine receptors and signaling
- Ferroptosis and cancer prognosis
- Lung Cancer Treatments and Mutations
- Cancer, Hypoxia, and Metabolism
- Cancer Cells and Metastasis
- Radiomics and Machine Learning in Medical Imaging
- Biosimilars and Bioanalytical Methods
- Lung Cancer Research Studies
- Histone Deacetylase Inhibitors Research
- Immune cells in cancer
- Melanoma and MAPK Pathways
- Chronic Lymphocytic Leukemia Research
- BRCA gene mutations in cancer
- Immune Cell Function and Interaction
Roswell Park Comprehensive Cancer Center
2014-2025
University at Buffalo, State University of New York
1965-2024
University of Massachusetts Chan Medical School
2023
Shree Guru Gobind Singh Tricentenary University
2023
Rochester General Hospital
2020
The University of Texas MD Anderson Cancer Center
2020
Moffitt Cancer Center
2020
University Hospitals Seidman Cancer Center
2019
State University of New York
2015
Princess Margaret Cancer Centre
2012
This selection from the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology focuses on considerations comprehensive care of AYA patients with cancer. Compared older adults cancer, have unique needs regarding treatment, fertility counseling, psychosocial behavioral issues, supportive services. The complete version addresses additional aspects caring patients, including risk factors, screening, diagnosis, survivorship.
Abstract Purpose: Increased β-adrenergic receptor (β-AR) signaling has been shown to promote the creation of an immunosuppressive tumor microenvironment (TME). Preclinical studies have that abrogation this pathway, particularly β2-AR, provides a more favorable TME enhances activity anti–PD-1 checkpoint inhibitors. We hypothesize blocking stress-related pathways would improve response immune inhibitors in patients. Here, we report results dose escalation nonselective β-blocker (propranolol)...
Tumor dormancy is a crucial mechanism responsible for the late recurrence of breast cancer. Thus, we investigated clinical relevance expression NR2F1, known biomarker.A total 6758 transcriptomes bulk tumors from multiple cancer patient cohorts and two single-cell sequence were analyzed.Breast (BC) with high NR2F1 enriched TGFβ signaling, metastases, stem cell-related pathways. Cell proliferation-related gene sets suppressed, MKi67 was lower in BC. In Nottingham grade, found to be lower....
Breast cancer (BC) patients experience increased stress with elevated cortisol levels, increasing risk of recurrence. Cortisol binds to a cytoplasmic receptor, glucocorticoid receptor (GR) encoded by GR gene (NR3C1). We hypothesized that not only cells, but even immune cells in the tumor microenvironment (TME) may contribute expression bulk and influence prognosis. To test this, mRNA data was accessed from METABRIC TCGA. “High” “low” based on highest lowest quartiles NR3C1 expression,...
Mild cold stress induced by housing mice with a 4T1 triple-negative breast cancer (TNBC) cell implantation model at 22 °C increases tumor growth rate pro-tumorigenic immune microenvironment (lower CD8 +T cells, higher myeloid-derived suppressor cells (MDSCs) and regulatory T-cells (Tregs)). Since also activates thermogenesis, we hypothesized that enhanced thermogenesis is associated more aggressive biology unfavorable (TME) in TNBC patients. A total of 6479 patients from METABRIC, TCGA,...
Aim: Patients receiving checkpoint inhibitors (CPI) are frequently on other medications for co-morbidities. We explored the impact of concomitant medication use outcomes. Materials & methods: 210 metastatic cancer patients CPI were identified and association between immune-related adverse events with clinical outcomes was determined. Results: Aspirin, metformin, β-blockers statins not shown to have any statistically significant difference benefit. 26.3% benefit developed rash versus 11.8%...
Abstract The development of novel anti-HER2 drugs opens new treatment options for women with breast cancers, including lower expression HER2. epidemiology and clinical outcome metastatic HER2-low cancer remain not well described. We designed a retrospective cohort study the 2010–2017 National Cancer Database (NCDB) was to compare overall survival HER2-zero de novo systemic therapy. Multivariable Cox regression models were performed estimate hazard ratios (HR), adjusting sociodemographic...
Abstract Purpose To analyze the association between Neighborhood Deprivation Index (NDI) and clinical outcomes of locoregional breast cancer (BC). Methods Surveillance, Epidemiology End Results (SEER) database is queried to evaluate overall survival (OS) disease-specific (DSS) early- stage BC patients diagnosed 2010 2016. Cox multivariate regression was performed measure NDI (Quintiles corresponding most deprivation (Q1), above average (Q2), (Q3), below (Q4), least (Q5)) OS/DSS. Of 88,572...
Background Presence of cytotoxic T lymphocytes (CTL) in the tumor microenvironment (TME) predicts effectiveness cancer immunotherapies. The ability toll-like receptor 3 (TLR3) ligands, interferons (IFNs) and COX2 inhibitors to synergistically induce CTL-attracting chemokines (but not regulatory cell (Treg)-attractants) TME, but healthy tissues, observed our preclinical studies, suggested that their systemic application can reprogram local TMEs. Methods Six evaluable patients (33–69 years)...
"HSR25-170: Investigating Socioeconomic and Racial Disparities in Pathologic Response Survival Outcomes Triple-Negative Breast Cancer Post-Neoadjuvant Chemotherapy: Insights From the National Database" published on 28 Mar 2025 by Comprehensive Network.
Abstract Background: Anti PD-1/ PD-L1 agents have been approved for a number of cancers and prolong progression-free survival (PFS) overall (OS) in subset patients. However, not all patients benefit from these checkpoint inhibitors there are no efficacious treatment options who resistant or refractory to those agents.CTX-8371 is bispecific, tetravalent antibody consisting an anti-PD-1 IgG1 with two anti-PD-L1 Fabs fused at the C-terminus aglycosylated Fc fragment through (G4S)4 linkers....
Chemotherapeutic agents are known to exert anti-tumor effects by not only invoking cytotoxic effects, but also altering both the immune profile and metabolic milieu. These alterations milieu circulating metabolome may be leveraged for designing rationale drug combinations with immunotherapeutic agents, once chemotherapy fails. Using publicly available transcriptomic data breast cancer (BC) patients treated neoadjuvant (GSE162187), we assessed transcriptional that coincide response...
Older patients with acute myeloid leukemia (AML) have poor outcomes standard induction chemotherapy. We retrospectively reviewed our institute's experience epigenetic (Epi) versus cytarabine‐ and anthracycline‐based intensive chemotherapy (IC) as in newly diagnosed AML aged 60 years older. One hundred sixty‐seven ( n = 84, IC; 83, Epi) were assessed; 69 received decitabine 14 azacitidine. Baseline characteristics between the IC Epi patient cohorts not statistically different except for age,...
Abstract Background BRCAness is a characteristic feature of homologous recombination deficiency (HRD) mimicking BRCA gene mutation in breast cancer. We hypothesized that measure to quantify causes synthetic lethality mutated tumors will identify responders PARP inhibitors. Methods A total 6753 cancer patients from 3 large independent cohorts were analyzed. score was generated by transcriptomic profiling using set variation analysis algorithm on 34 BRCA1-mutation related genes selected high...